STOK (Stoke Therapeutics) Minority Interest: $0.00 Mil (As of Mar. 2026)


STOK Stoke Therapeutics Inc STOK
45 GF Score
Price $31.38
GF Value $10.09
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Stoke Therapeutics Minority Interest?

Stoke Therapeutics STOK -4.47% 45 Minority Interest is $0.00 Mil as of Mar. 2026. GuruFocus rates STOK with a GF Score™ of 45/100 and a GF Value™ of $10.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Stoke Therapeutics's minority interest for the quarter that ended in Mar. 2026 was $0.00 Mil.

Stoke Therapeutics Minority Interest Historical Data

* Premium members only.

The historical data trend for Stoke Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stoke Therapeutics Minority Interest Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Stoke Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STOK
45GF Score
Stoke Therapeutics Inc STOK
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stoke Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of $0.00 Mil mean?
Stoke Therapeutics (STOK) has a Minority Interest of $0.00 Mil as of Mar. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Stoke Therapeutics.
Is Stoke Therapeutics' Minority Interest too high?
Stoke Therapeutics' current Minority Interest is $0.00 Mil. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' Minority Interest compare to VRDN and ZLAB?
Stoke Therapeutics' Minority Interest of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Stoke Therapeutics. Stoke Therapeutics's current Minority Interest is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.09, compared to a current price of $31.38 — trading 211% above its estimated fair value. The current Minority Interest is $0.00 Mil. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current Minority Interest is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stoke Therapeutics (STOK) Overvalued in 2026?

Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued. The current stock price of $31.38 is trading 211% above its estimated GF Value™ of $10.09. GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.

Key valuation signals for STOK:

  • Minority Interest: $0.00 Mil
  • GF Value™: $10.09 vs. price of $31.38 (211% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stoke Therapeutics Business Description

Other Exchanges 0GT:Germany
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score

Get the complete analysis for STOK

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.38
Price
$10.09
GF Value